COVID-19 vaccines made by Johnson & Johnson(J&J) and Novavax have also been shown to offer weaker protection against B.1.351 (also known as 501.V2), the SARS-CoV-2 variant that now causes the vast majority of all infections in South Africa, than against older variants. The vaccines’ efficacy against mild disease in South Africa was 57% for J&J and 49% for Novavax—lower than in any other country they were tested. The stakes are high globally for this particular vaccine because its makers, AstraZeneca and the University of Oxford, hope it will be widely used in developing countries; they project they can produce 3 billion doses this year for about $3 each, far more product at a far lower price than any other vaccine shown to offer protection against COVID-19. Madhi and the research team had planned to report the results on 8 February, but the Financial Times ran a story two days earlier based on a leaked copy of the findings. Madhi and his ...
everything you need to know....